Company news

Veracyte, Inc. news in 2021

Veracyte, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis

December 13, 2021

Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test

November 23, 2021

Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021

November 12, 2021

Veracyte Announces Third Quarter 2021 Financial Results

November 8, 2021

Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia

November 4, 2021

New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis

November 2, 2021

Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities

November 1, 2021

New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery

October 25, 2021

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

October 24, 2021

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

October 13, 2021

New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

October 12, 2021

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

October 11, 2021

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment

October 10, 2021

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

October 10, 2021

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

October 5, 2021

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

September 13, 2021

Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology

August 31, 2021

Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

August 30, 2021

Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year

August 22, 2021

Veracyte Completes Acquisition of HalioDx

August 2, 2021

Veracyte Announces Second Quarter 2021 Financial Results

July 28, 2021

New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer

July 26, 2021

Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth

July 11, 2021

Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021

July 7, 2021

Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion

July 7, 2021

Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team

June 30, 2021

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer

June 13, 2021

Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder

June 3, 2021

CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences

June 1, 2021

Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth

May 31, 2021

Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples

May 25, 2021

Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier

May 24, 2021

Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection

May 18, 2021

Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy

May 13, 2021

Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis

May 13, 2021

Veracyte, Inc. Announces CEO Succession Plan

May 9, 2021

Veracyte Announces First Quarter 2021 Financial Results

May 9, 2021

Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

May 3, 2021

Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO

April 28, 2021

Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis

April 26, 2021

Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

April 19, 2021

Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference

April 18, 2021

Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results

April 14, 2021

Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test

April 13, 2021

Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

April 1, 2021

Veracyte Appoints Muna Bhanji to Its Board of Directors

March 21, 2021

Veracyte Completes Acquisition of Decipher Biosciences

March 14, 2021

Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

February 16, 2021

Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

February 9, 2021

Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 8, 2021

Older news releases →

Calls in 2021

Decks in 2021